Pregnancy in Parkinson's disease: Case report and discussion

Expert Review of Neurotherapeutics

Volumn 8, Issue 12, 2008, Pages 1799-1805

  Robottom, Bradley J ^a   Mullins, Roger J ^a   Shulman, Lisa M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Amantadine; COMT inhibitor; Dopamine agonist; Estrogen; Levodopa; MAO B inhibitor; Parkinson's disease; Pregnancy; Progression

Indexed keywords

ROPINIROLE; TRIHEXYPHENIDYL;

ADULT; ANAMNESIS; BREAST FEEDING; CASE REPORT; CLINICAL FEATURE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HUMAN; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PATIENT COUNSELING; PREGNANCY; REVIEW; TREATMENT RESPONSE;

ADULT; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; ESTROGENS; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 57749204578     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.12.1799     Document Type: Review

References (51)

1. Shulman LM, Minager A, Weiner WJ. The effect of pregnancy in Parkinson's disease. Mov. Disord. 15, 132-135 (2000). • Detailed case report, including data on physical and mental health during pregnancy and a literature review.
2. Scott M, Chowdhury M. Pregnancy in Parkinson's disease: unique case report and review of the literature. Mov. Disord. 20, 1078-1079 (2005).
3. Mucchiut M, Belgrado E, Cutuli D, Antonini A, Bergonzi P. Pramipexole-treated Parkinson's disease during pregnancy. Mov. Disord. 19, 1114-1115 (2004).
4. Golbe LI. Parkinson's disease and pregnancy. Neurology 37, 1245-1249 (1987). •• Largest case series available regarding the topic of pregnancy in Parkinson's disease (PD).
5. Routiot T, Lurel S, Denis E, Barbarino-Monnier P. Parkinson's disease and pregnancy: case report and literature review. J. Gynecol. Obstet. Biol. Reprod. (Paris) 29(5), 454-457 (2000).
6. Kupsch A, Oertel WH. Selegiline, pregnancy, and Parkinson's disease. Mov. Disord. 13(1), 175-176 (1998).
7. Hagell P, Odin P, Vinge E. Pregnancy in Parkinson's disease: a review of the literature and a case report. Mov. Disord. 13(1), 34-38 (1998).
8. Jacquemard F, Palaric JC, Allain H, Giraud JR. Parkinson disease and pregnancy. Apropos of a case. J. Gynecol. Obstet. Biol. Reprod. (Paris) 19(4), 461-463 (1990).
9. Cook DG, Klawans HL. Levodopa during pregnancy. Clin. Neuropharmacol. 8, 93-95 (1985).
10. De Mari M, Zenzola A, Lamberti P. Antiparkinsonian treatment in pregnancy. Mov. Disord. 17(2), 428-429 (2002).
11. Lindh J. Short episode of seizures in a newborn of a mother treated with levodopa/carbidopa/entacapone and bromocriptine. Mov. Disord. 22(10), 1515-1519 (2007).
12. Swerdlow RH, Parker WD, Currie LJ et al. Gender ratio differences between Parkinson's disease patients and their affected relatives. Parkinsonism Relat. Disord. 7(2), 129-133 (2001).
13. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52(6), 1214-1220 (1999). • Unique epidemiological study based on the availability of over 15 years of data collection as part of the Rochester Epidemiology Project.
14. Van Den Eeden SK, Tanner CM, Bernstein AL et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157(11), 1015-1022 (2003).
15. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66(5), 664-671 (2006).
16. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68(1), 20-28 (2007).
17. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch. Neurol. 58, 1611-1615 (2001).
18. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328, 176-183 (1993).
19. Rajput MI, Rajput A, Rajput AH. Gender differences at Parkinson's disease presentation in a movement disorders clinic. Mov. Disord. 19(9), 1118-1134 (2004).
20. Scott B, Borgman A, Engler H, Johnels B, Aquilonius SM. Gender differences in Parkinson's disease symptom profile. Acta Neurol. Scand. 102(1), 37-43 (2000).
21. Malecki EA, Vaughan CG, Anderson KE et al. What symptoms are most troubling to patients with Parkinson's disease. Neurology 62(Suppl. 5), A50 (2004).
22. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann. Neurol. 39, 37-45(1996).
23. Zappia M, Annesi G, Nicoletti G et al. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 62, 601-605 (2005).
24. Zappia M, Crescibene L, Arabia G et al. Body weight influences pharmacokinetics of levodopa in Parkinson's disease. Clin. Neuropharmacol. 25(2), 79-82 (2002).
25. Growden JH, Kieburtz K, McDermott MP et al. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology 50, 1227-1231 (1998).
26. Martenelli P, Contin M, Scaglione C, Riva R, Albani F, Baruzzi A. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences. Neurol. Sci. 24(3), 192-193 (2003).
27. Kompoliti K. Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. Neurology 58, 1412-1422 (2002).
28. Wright CE, Sisson TL, Ichpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J. Clin. Pharmacol. 37(6), 520-525 (1997).
29. Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin. Pharmacokinet. 39(4), 243-254 (2000).
30. Jorga KM. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers. Neurology 50(Suppl. 5), S31-S38 (1998).
31. Parashos SA. Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease. Clin. Neuropharmacol. 27(3), 119-123 (2004).
32. Thulin P, Carter JH, Nichols MD, Kurth M, Nutt JG. Menstrual-cycle related changes in Parkinson's disease. Neurology 46, A376 (1996).
33. Horstink MW, Strijkse E, Dulzen DE. Estrogen and Parkinson's disease. Adv. Neurol. 91, 107-114 (2003).
34. Quinn NP, Marsden CD. Menstrual-related fluctuations in Parkinson's disease. Mov. Disord. 1, 85-87 (1986).
35. Kompoliti K, Comella CL, Jaglin JA, Leurgans S, Raman R, Goetz CG. Menstrual-related changes in motoric function in women with Parkinson's disease. Neurology 55(10), 1572-1575 (2000).
36. Ragonese P, D'Amelio M, Salemi G et al. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62, 2010-2014 (2004). • Intriguing epidemiological study supporting the theory that an overall reduction in estrogen leads to an increased risk of PD.
37. Pasqualini C, Olivier V, Guibert B, Frain O, Leviel V. Acute stimulatory effect of estradiol on striatal dopamine synthesis. J. Neurochem. 65(4), 1651-1657 (1995).
38. Xiao L, Becker JB. Effects of estrogen agonists on amphetamine-stimulated striatal dopamine release. Synapse 29(4), 379-391 (1998).
39. Disshon KA, Boja JW, Dluzen DE. Inhibition of striatal dopamine transporter activity by 17 β-estradiol. Eur. J. Pharmacol. 345(2), 207-211 (1998).
40. Bazzett TJ, Becker JB. Sex differences in the rapid and acute effects of estrogen on striatal D2 dopamine receptor binding. Brain Res. 637, 163-172 (1994).
41. Kuppers E, Ivanova T, Karolezak M, Beyer C. Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons. J. Neurocytol. 29, 375-385 (2000).
42. Kita T, Wagner GC, Nakashima TJ. Current research on methamphetamine- induced neurotoxicity: animal models of monoamine disruption. Pharmacol. Sci. 92(3), 178-195 (2003).
43. Langston JW, Langston EB, Irwin I. MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurol. Scand. Suppl. 100, 49-54 (1984).
44. Gao X, Dluzen DE. Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system. Neuroscience 103(2), 385-394 (2001).
45. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci. 20, 8604-8609 (2000).
46. Behl C, Skutella T, Lezoualch F et al. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 51, 535-541 (1997).
47. Woolley CS. Estrogen-mediated structural and functional synaptic plasticity in the female rat hippocampus. Horm. Behav. 34, 140-148 (1998).
48. Kenchappa RS, Reandrancth V. Glutaredoxin is essential for maintenance of brain mitochondrial complex I: studies with MPTP. FASEB J. 17(6), 717-719 (2003).
49. Kenchappa RS, Diawaker L, Annepu J, Ravindranath V. Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J. 18, 1102-1104 (2004).
50. Merchant CA, Cohen G, Mytilineous C et al. Human transplacental transmission of carbidopa/levodopa. Neurology 44(Suppl. 2), A247-A248 (1994).
51. Turkalj I, Braun P, Krupp P. Surveillance of bromocriptine in pregnancy. JAMA 247, 1589-1591 (1982).